Business
Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting
Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM)
About this update from Aclarion, Inc.
[{"type":"text","content":" Nociscan cost-effectiveness abstract poster highlights dominance over provocative discography. The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023. Founded in 1979, SMDM promotes scientific and methodological rigor in health care decision research and its application to health policy and clinical care. Highlighting the importance of the cost savings and improved outcomes associated with Nociscan, SMDM represents the third society meeting, showcasing the Economic Value Analysis of Low back pain (EVAL) study in 2023 BROOMFIELD, CO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their Nociscan cost-effectiveness poster will be showcased at the 45th Annual Society for Medical Decision Making meeting, October 22-25, 2023. The cost-effectiveness study comparing Nociscan to provocative discography was performed at the Center for Disruptive Musculoskeletal Innovations (CDMI) through a National Science Foundation (NSF) grant and sponsored by Aclarion. The abstract highlights that Nociscan statistically dominates provocative discography (PD) because PD is both more costly and less effective. \"An evidence-based process for accurate identification of a source for low back pain is valuable to improve cost-effectiveness of operative and non-operative management strategies,\" said Leslie Wilson, PhD, Professor in the Department of Medicine and the Department of Clinical Pharmacy at University of California San Francisco. “The economic model includes a decision-tree comparing Nociscan with PD based on a comprehensive set of peer-reviewed data. The incremental cost-effectiveness ratio (ICER) confirms that Nociscan dominates PD, with a Monte Carlo sensitivity analysis illustrating Nociscan dominates from 40-85% over a wide willingness-to-pay range. In total, Nociscan can save the US healthcare system from $283M to $441M annually.” Chronic low back pain (cLBP) is a global healthcare problem, with approximately 266 million people worldwide suffering from degenerative spine disease and low back pain. Conventional imaging and diagnostic...